848192-96-1

Basic information

• Product Name: 3-(trifluoromethyl)azetidin-3-ol hydrochloride
• Synonyms: 3-(trifluoromethyl)azetidin-3-ol hydrochloride;3-Hydroxy-3-(trifluoroMethyl)azetidine hydrochloride;3-TrifluoroMethyl-azetidin-3-ol;3-(TrifluoroMethyl)-3-azetidinol HCl;3-(trifluoroMethyl)-3-azetidinolhydrochloride
• CAS NO: 848192-96-1
• Molecular Formula: C₄H₆F₃NO*ClH
• Molecular Weight: 177.552
• Mol File: 848192-96-1.mol
• Article Data: 5

Chemical Properties

• Appearance: White to yellow/Powder
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 3-(trifluoromethyl)azetidin-3-ol hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(trifluoromethyl)azetidin-3-ol hydrochloride(848192-96-1)
• EPA Substance Registry System: 3-(trifluoromethyl)azetidin-3-ol hydrochloride(848192-96-1)

Safety Data

• Hazardous Substances Data: 848192-96-1(Hazardous Substances Data)

Usage

Uses

3-(Trifluoromethyl)azetidin-3-ol Hydrochloride is used for benzoxaborole antimalarial agent.

InChI:InChI=1/C4H6F3NO.ClH/c5-4(6,7)3(9)1-8-2-3;/h8-9H,1-2H2;1H

Upstream product

• 848192-92-7 1-benzhydryl-3-(trifluoromethyl)azetidin-3-ol 

Downstream Products

• 1352065-34-9 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(3-hydroxy-3-(trifluoromethyl)azetidin-1-yl)butan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 

Relevant articles and documents

Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate

Carboxamide pyrazinyloxy benzoxaboroles were investigated with the goal to identify a molecule with satisfactory antimalarial activity, physicochemical properties, pharmacokinetic profile, in vivo efficacy, and safety profile. This optimization effort discovered 46, which met our target candidate profile. Compound 46 had excellent activity against cultured Plasmodium falciparum, and in vivo against P. falciparum and P. berghei in infected mice. It exhibited good PK properties in mice, rats, and dogs. It was highly active against the other 11 P. falciparum strains, which are mostly resistant to chloroquine and pyrimethamine. The rapid parasite in vitro reduction and in vivo parasite clearance profile of 46 were similar to those of artemisinin and chloroquine, two rapid-acting antimalarials. It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg. The combined properties of this novel benzoxaborole support its progression to preclinical development.

Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

QUINAZOLINE-2, 4-DIONES AS ANTIBACTERIAL AGENTS

Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of